These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23866929)

  • 21. Large-cell neuroendocrine carcinoma of lung with epidermal growth factor receptor (EGFR) gene mutation and co-expression of adenocarcinoma markers: a case report and review of the literature.
    Sakai Y; Yamasaki T; Kusakabe Y; Kasai D; Kotani Y; Nishimura Y; Itoh T
    Multidiscip Respir Med; 2013 Jul; 8(1):47. PubMed ID: 23866929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high-grade neuroendocrine carcinoma.
    Zhao J; Shao J; Zhao R; Li R; Yu K; Zhu L; Zhang J
    Thorac Cancer; 2018 Jan; 9(1):129-135. PubMed ID: 29120087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma.
    Iyoda A; Travis WD; Sarkaria IS; Jiang SX; Amano H; Sato Y; Saegusa M; Rusch VW; Satoh Y
    Exp Ther Med; 2011 Nov; 2(6):1041-1045. PubMed ID: 22977617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
    Yanagisawa S; Morikawa N; Kimura Y; Nagano Y; Murakami K; Tabata T
    Respirology; 2012 Nov; 17(8):1275-7. PubMed ID: 22943430
    [No Abstract]   [Full Text] [Related]  

  • 30. Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment.
    Lu HY; Mao WM; Cheng QY; Chen B; Cai JF; Wang XJ; Wang Z; Xie FJ
    Oncol Lett; 2012 Jun; 3(6):1288-1292. PubMed ID: 22783435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
    Lu HY; Sun WY; Chen B; Zhang YP; Cai JF; Su D; Wang Z; Zheng YQ; Ma SL
    Neoplasma; 2012; 59(1):100-4. PubMed ID: 22103903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
    De Pas TM; Giovannini M; Manzotti M; Trifirò G; Toffalorio F; Catania C; Spaggiari L; Labianca R; Barberis M
    J Clin Oncol; 2011 Dec; 29(34):e819-22. PubMed ID: 22042963
    [No Abstract]   [Full Text] [Related]  

  • 33. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
    Sequist LV; Waltman BA; Dias-Santagata D; Digumarthy S; Turke AB; Fidias P; Bergethon K; Shaw AT; Gettinger S; Cosper AK; Akhavanfard S; Heist RS; Temel J; Christensen JG; Wain JC; Lynch TJ; Vernovsky K; Mark EJ; Lanuti M; Iafrate AJ; Mino-Kenudson M; Engelman JA
    Sci Transl Med; 2011 Mar; 3(75):75ra26. PubMed ID: 21430269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
    Yi ES; Boland JM; Maleszewski JJ; Roden AC; Oliveira AM; Aubry MC; Erickson-Johnson MR; Caron BL; Li Y; Tang H; Stoddard S; Wampfler J; Kulig K; Yang P
    J Thorac Oncol; 2011 Mar; 6(3):459-65. PubMed ID: 21278610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
    Travis WD; Brambilla E; Noguchi M; Nicholson AG; Geisinger KR; Yatabe Y; Beer DG; Powell CA; Riely GJ; Van Schil PE; Garg K; Austin JH; Asamura H; Rusch VW; Hirsch FR; Scagliotti G; Mitsudomi T; Huber RM; Ishikawa Y; Jett J; Sanchez-Cespedes M; Sculier JP; Takahashi T; Tsuboi M; Vansteenkiste J; Wistuba I; Yang PC; Aberle D; Brambilla C; Flieder D; Franklin W; Gazdar A; Gould M; Hasleton P; Henderson D; Johnson B; Johnson D; Kerr K; Kuriyama K; Lee JS; Miller VA; Petersen I; Roggli V; Rosell R; Saijo N; Thunnissen E; Tsao M; Yankelewitz D
    J Thorac Oncol; 2011 Feb; 6(2):244-85. PubMed ID: 21252716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report.
    Shiao TH; Chang YL; Yu CJ; Chang YC; Hsu YC; Chang SH; Shih JY; Yang PC
    J Thorac Oncol; 2011 Jan; 6(1):195-8. PubMed ID: 21178714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
    Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
    Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.
    Brevet M; Arcila M; Ladanyi M
    J Mol Diagn; 2010 Mar; 12(2):169-76. PubMed ID: 20093391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
    Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
    Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.